The two drugs have a different set of broader indications, with Zepbound also approved to treat sleep apnea in people with obesity, for example
BPC-157, a remarkable peptide, has emerged as a potential therapeutic agent for improving bone and joint health, particularly in cases of tendon to bone damage
Maintaining healthy nutrition, physical activity, and regular medical follow-up remains important
if they do, discuss modifying the activity with your physical therapist
Proven Weight Loss: Clinical studies, including the SURMOUNT-1 trial, have shown that Mounjaro can help people with obesity (without diabetes) lose an average of 15% to over 20% of their body weight